Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma.

Human Pathology
Xiao HuangLei Huo

Abstract

The Dako 28-8, Dako 22C3, and Ventana SP142 assays are among the approved programmed death ligand 1 (PD-L1) immunohistochemical companion/complementary diagnostics associated with cancer treatment. To address the concordance of these assays in triple-negative breast cancer (TNBC), we examined PD-L1 expression in 98 TNBC tumors and compared the positive rates using the three assays and three scoring methods: immune cell (IC), tumor cell (TC), and combined tumor cell and immune cell (TCIC) (an equivalent to combined positive score, or CPS). The positive rate for PD-L1 expression with a 1% cutoff was highest with 28-8, followed by the 22C3. These two assays demonstrated almost perfect or substantial agreement in all three scores. There was less agreement between SP142 and the other assays. Using the IC score or the TCIC score at a 1% cutoff (CPS 1), 4% of tumors were positive for PD-L1 with SP142 but negative with the other assays. Using SP142 with a 1% cutoff as a reference, the optimal cutoff for best agreement was at 1% for IC, 30% for TC, and 2% for TCIC (CPS 2) with the other two assays. A 2% cutoff for the 22C3 TCIC (CPS 2) yielded the best agreement with SP142 1% IC cutoff (kappa 0.65). Our study showed the lowest positive ...Continue Reading

References

Jan 1, 2007·Archives of Pathology & Laboratory Medicine·Antonio C WolffUNKNOWN American Society of Clinical Oncology/College of American Pathologists
Sep 1, 2015·Applied Immunohistochemistry & Molecular Morphology : AIMM·Therese PhillipsXiaoling Zhang
May 4, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rita NandaLaurence Buisseret
Jun 23, 2016·Applied Immunohistochemistry & Molecular Morphology : AIMM·Charlotte RoachKarina Kulangara
Dec 4, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Fred R HirschKeith M Kerr
Nov 28, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Shona HendryStephen B Fox
Dec 1, 2017·Applied Immunohistochemistry & Molecular Morphology : AIMM·Therese PhillipsHenrik Winther
Jan 19, 2018·Applied Immunohistochemistry & Molecular Morphology : AIMM·Bharathi VennapusaZachary Boyd
May 26, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Ming Sound TsaoFred R Hirsch
Oct 23, 2018·The New England Journal of Medicine·Peter SchmidUNKNOWN IMpassion130 Trial Investigators
Nov 27, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S AdamsP Schmid
Feb 27, 2020·The New England Journal of Medicine·Peter SchmidUNKNOWN KEYNOTE-522 Investigators

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.